See more : China Longyuan Power Group Corporation Limited (CLPXF) Income Statement Analysis – Financial Results
Complete financial analysis of Neumora Therapeutics, Inc. Common Stock (NMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neumora Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Dongfeng Motor Group Company Limited (DNFGY) Income Statement Analysis – Financial Results
- Fixstars Corporation (3687.T) Income Statement Analysis – Financial Results
- KL Acquisition Corp (KLAQ) Income Statement Analysis – Financial Results
- Doric Nimrod Air Three Limited (DNA3.L) Income Statement Analysis – Financial Results
- Blackboxstocks Inc. (BLBX) Income Statement Analysis – Financial Results
Neumora Therapeutics, Inc. Common Stock (NMRA)
About Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 668.00K | 2.70M | 1.55M | 0.00 |
| Gross Profit | -668.00K | -2.70M | -1.55M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 142.72M | 104.75M | 212.78M | 87.13M |
| General & Administrative | 45.48M | 31.12M | 24.55M | 8.39M |
| Selling & Marketing | -668.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 44.81M | 31.12M | 24.55M | 8.39M |
| Other Expenses | 0.00 | 405.00K | 11.00K | -3.75M |
| Operating Expenses | 187.53M | 135.87M | 237.32M | 95.52M |
| Cost & Expenses | 188.19M | 135.87M | 237.32M | 95.52M |
| Interest Income | 16.61M | 4.56M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 668.00K | 2.70M | 1.55M | 105.00K |
| EBITDA | -187.53M | -135.28M | -236.79M | -95.41M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -188.19M | -135.87M | -237.32M | -95.52M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -47.46M | 4.97M | 11.00K | -3.75M |
| Income Before Tax | -235.66M | -130.90M | -237.31M | -99.27M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 268.00K | -4.56M | 301.44K | -101.30K |
| Net Income | -235.93M | -130.90M | -237.31M | -99.27M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -0.86 | -1.56 | -0.65 |
| EPS Diluted | -1.49 | -0.86 | -1.56 | -0.65 |
| Weighted Avg Shares Out | 158.83M | 151.95M | 151.95M | 151.95M |
| Weighted Avg Shares Out (Dil) | 158.83M | 151.95M | 151.95M | 151.95M |
Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
Neumora's early-stage schizophrenia drug study put on hold
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
7 Stocks with Strong Insider Buying: December 2023
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
Source: https://incomestatements.info
Category: Stock Reports